Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors (Q46962964)
scientific article published on 24 February 2006
Language:
Current Data About Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
(P31) (Q13442814)
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P304) 866-873
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P433) 5
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P478) 17
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P577) Friday, February 24, 2006
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P921) (Q5452194)

(Q18936)
(P887)

(P1433) (Q326122)
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P1476) "Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors" (language: en)
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

(P2093) H Richly
(P1545) 1
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

B F Henning
(P1545) 2
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

P Kupsch
(P1545) 3
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

K Passarge
(P1545) 4
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

M Grubert
(P1545) 5
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

R A Hilger
(P1545) 6
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

O Christensen
(P1545) 7
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

E Brendel
(P1545) 8
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

B Schwartz
(P1545) 9
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

M Ludwig
(P1545) 10
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

C Flashar
(P1545) 11
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

R Voigtmann
(P1545) 12
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

M E Scheulen
(P1545) 13
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

S Seeber
(P1545) 14
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

D Strumberg
(P1545) 15
(P248)
(P698) 16500908
(P813) Tuesday, December 26, 2017
(P854) http://europepmc.org/abstract/MED/16500908

other details
description scientific article published on 24 February 2006

External Links
(P356) 10.1093/ANNONC/MDL017
(P698) 16500908
(P5875) 7276471